MID-VOLUME · HOSP-HEAVY
ciclesonide Side Effects
ciclesonide (also sold as Alvesco) sits MID-VOLUME #286 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 44.8% mention hospitalization (5,864 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 13,075
- FAERS reports
FDA Adverse Event Reporting System extract for ciclesonide. Stamp set WATCHLIST · DEATH-MARKED · HOSP-HEAVY. How figures are compiled.
ciclesonide: 44.8% mention hospitalization (5,864 reports). Death stamp DEATH-MARKED; volume band MID-VOLUME #286 of 524 by FAERS report count.
Mid-book FAERS page for ciclesonide (Alvesco) (13,075 reports). Signature HOSP-HEAVY. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2006–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ASTHMA leads 5,711 of 13,075 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (3,431 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 576 reports (4.4% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 334 |
| ASTHMA | 144 |
| DYSPNOEA | 140 |
| WHEEZING | 97 |
| PNEUMONIA | 86 |
| PRODUCTIVE COUGH | 73 |
| FORCED EXPIRATORY VOLUME DECREASED | 72 |
| OBSTRUCTIVE AIRWAYS DISORDER | 72 |
| ANXIETY | 71 |
| CONDITION AGGRAVATED | 66 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 64 |
| LUNG DISORDER | 64 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 64 |
| THROMBOSIS | 64 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 62 |
| ARTERIOSCLEROSIS | 61 |
| HAEMOPTYSIS | 61 |
| PAIN IN EXTREMITY | 61 |
| HYPOXIA | 60 |
| HYPOTHYROIDISM | 59 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (5,864, 44.8% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| ASTHMA | 3,280 |
| DYSPNOEA | 2,636 |
| WHEEZING | 2,226 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 1,446 |
| COUGH | 1,189 |
| PNEUMONIA | 1,156 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 1,103 |
| OBSTRUCTIVE AIRWAYS DISORDER | 1,033 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 974 |
| PRODUCTIVE COUGH | 966 |
| CONDITION AGGRAVATED | 693 |
| CHEST DISCOMFORT | 649 |
| MALAISE | 646 |
| FULL BLOOD COUNT ABNORMAL | 642 |
| FATIGUE | 636 |
| NASOPHARYNGITIS | 498 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 455 |
| BLOOD PRESSURE INCREASED | 446 |
| HEADACHE | 445 |
How to read ciclesonide FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-HEAVY)
FAERS holds 13,075 voluntary reports linked to ciclesonide (Alvesco), 2006-2025. Death is listed on 576 (4.4%). Hospitalization appears on 5,864 (44.8%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-MARKED · HOSP-HEAVY as signal-detection rates next to 44.8% mention hospitalization (5,864 reports).
Read with ciclesonide
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-HEAVY stamps.
ABS(total_reports) peer at 13,113 FAERS cases (Δ 38 heavier vs ciclesonide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 12,966 FAERS cases (Δ 109 lighter vs ciclesonide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 12,919 FAERS cases (Δ 156 lighter vs ciclesonide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 12,855 FAERS cases (Δ 220 lighter vs ciclesonide); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 57.7 pp vs ciclesonide's DEATH-MARKED): CASELOAD · HOSP-MID.
ciclesonide stamps DEATH-MARKED · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.